Assembly Biosciences Files 8-K

Ticker: ASMB · Form: 8-K · Filed: Dec 26, 2024 · CIK: 1426800

Assembly Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyAssembly Biosciences, INC. (ASMB)
Form Type8-K
Filed DateDec 26, 2024
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, financial-statements

TL;DR

ASMB filed an 8-K on 12/26/24. Standard corporate update.

AI Summary

Assembly Biosciences, Inc. filed an 8-K on December 26, 2024, reporting other events and financial statements. The company, formerly known as Ventrus Biosciences Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and other events, which provides transparency to investors about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any significant new risks or material adverse information.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Assembly Biosciences, Inc.?

The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of December 26, 2024.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on December 26, 2024.

What was Assembly Biosciences, Inc. formerly known as?

Assembly Biosciences, Inc. was formerly known as Ventrus Biosciences Inc.

In which state is Assembly Biosciences, Inc. incorporated?

Assembly Biosciences, Inc. is incorporated in Delaware.

What is the business address of Assembly Biosciences, Inc.?

The business address of Assembly Biosciences, Inc. is Two Tower Place, 7th Floor, South San Francisco, California 94080.

Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-12-26 08:25:41

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On December 26, 2024, Assembly Biosciences, Inc. (the "Company") issued a press release announcing interim results from its ongoing Phase 1b clinical study evaluating its investigational next-generation capsid assembly modulator candidate ABI-4334 in participants with chronic hepatitis B virus infection. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release dated December 26, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Assembly Biosciences, Inc. Date: December 26, 2024 By: /s/ John O. Gunderson John O. Gunderson VP, General Counsel and Corporate Secretary 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing